AUTHOR=Zhu Jiting , Zhang Yuanyuan , Li Runyun , Lin Yi , Fu Ying , Yan Yaping , Zhu Wenli , Wang Ning , Zhang Zaiqiang , Xu Guorong 

TITLE=Anti-ganglioside Antibodies in Guillain-Barre Syndrome: A Novel Immunoblotting-Panel Assay

JOURNAL=Frontiers in Neurology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.760889

DOI=10.3389/fneur.2021.760889

ISSN=1664-2295

ABSTRACT=<p><bold>Objective:</bold> This study aimed to determine the diagnostic efficiency of a novel immunoblotting detection assay for anti-ganglioside antibodies (AGAs) in the Guillain–Barre syndrome (GBS).</p><p><bold>Method:</bold> Serum immunoglobulin (IgG and IgM) of AGAs were measured in 121 participants from a registered cohort study of immune-mediated neuropathies and 29 healthy controls by immunoblotting panel assay. Sensitivity, specificity, and positive predictive value (PPV) of the assay were compared to calculate the diagnostic accuracy.</p><p><bold>Result:</bold> In our cohort, any of the AGAs were positive in 42.4% of the GBS patients. The sensitivity and specificity of AGAs (both IgG and IgM) in the diagnosis of GSB were 42 and 76% while for IgG-AGAs were 35 and 87%. AGAs positivity had a significant association with the AMAN subtype (<italic>P</italic> = 0.0004), and the sensitivity, specificity of AGAs in AMAN were 86, 69%, respectively with high (AUC = 0.78, <italic>p</italic> = 0.002) discriminative powers. GM1-IgG AGA was more common and specific to AMAN patients than other GBS forms (<italic>p</italic> = 0.008).</p><p><bold>Conclusion:</bold> Our novel immunoblotting detection assay could complement GBS diagnosis. IgG-AGAs were more likely to be detected in GBS, and GM1-IgG AGA could assist AMAN diagnosis.</p>